for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Emergent Biosolutions Inc

EBS.N

Latest Trade

52.39USD

Change

-1.45(-2.69%)

Volume

111,906

Today's Range

52.36

 - 

53.71

52 Week Range

52.36

 - 

127.18

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
53.84
Open
53.61
Volume
111,906
3M AVG Volume
10.11
Today's High
53.71
Today's Low
52.36
52 Week High
127.18
52 Week Low
52.36
Shares Out (MIL)
53.70
Market Cap (MIL)
2,891.25
Forward P/E
6.85
Dividend (Yield %)
--

Next Event

Emergent BioSolutions Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual)

Latest Developments

More

Emergent Says Working With AstraZeneca On Documentation For US Govt COVID-19 Vaccine Dose Shipments: Conf Call

Emergent Biosolutions Reports Financial Results For Second Quarter 2021

Emergent BioSolutions - Second Option Exercise Was Made Under Emergent's Existing 10-Year Contract Awarded By ASPR On August 30, 2019

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Emergent Biosolutions Inc

Emergent BioSolutions Inc. is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs). The PHTs operates through two categories: Chemical, Biological, Radiological and Nuclear, as well as explosive-related threats and emerging infectious diseases. It operates through four business units: Vaccines and Anti-infectives; Antibody Therapeutics; Devices, and Contract Manufacturing. Vaccines and Anti-infectives business unit consists of BioThrax, which is for the general use prophylaxis and post-exposure prophylaxis of anthrax disease. Devices business unit consists of marketed products, such as Reactive Skin Decontamination Lotion Kit (RSDL) and Trobigard (atropine sulfate, obidoxime chloride).

Industry

Biotechnology & Drugs

Contact Info

400 Professional Dr Ste 400

GAITHERSBURG, MD

20879-3457

United States

+1.240.6313200

https://emergentbiosolutions.com/

Executive Leadership

Fuad Nancy El-Hibri

Executive Chairman of the Board

Robert G. Kramer

President, Chief Executive Officer, Director

Richard S. Lindahl

Chief Financial Officer, Executive Vice President, Treasurer

Adam Havey

Chief Operating Officer, Executive Vice President

Katherine Strei

Executive Vice President - Human Resources and Communications, Chief Human Resources Officer

Key Stats

2.38 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.8K

2019

1.1K

2020

1.6K

2021(E)

1.8K
EPS (USD)

2018

2.330

2019

2.910

2020

7.880

2021(E)

7.864
Price To Earnings (TTM)
9.79
Price To Sales (TTM)
1.69
Price To Book (MRQ)
1.87
Price To Cash Flow (TTM)
6.90
Total Debt To Equity (MRQ)
55.32
LT Debt To Equity (MRQ)
53.46
Return on Investment (TTM)
12.71
Return on Equity (TTM)
11.12

Latest News

Latest News

Emergent to make Providence Therapeutics potential COVID-19 vaccine

Emergent BioSolutions Inc signed a five-year agreement with Canadian biotechnology company Providence Therapeutics to develop and manufacture its COVID-19 vaccine candidate for about $90 million.

Emergent to make Providence Therapeutics' potential COVID-19 vaccine

Emergent BioSolutions Inc signed a five-year agreement with Providence Therapeutics to develop and manufacture its COVID-19 vaccine candidate, the companies said on Tuesday.

Emergent's COVID-19 plasma therapy to be tested in NIH-sponsored study

The National Institutes of Health has initiated a late-stage study to test plasma-derived COVID-19 therapies including Emergent BioSolutions Inc's candidate for those at high risk of disease progression, the drug developer said.

UPDATE 1-Emergent's COVID-19 plasma therapy to be tested in NIH-sponsored study

The National Institutes of Health has initiated a late-stage study to test plasma-derived COVID-19 therapies including Emergent BioSolutions Inc's candidate for those at high risk of disease progression, the drug developer said.

FDA to allow export of certain lots of AstraZeneca COVID-19 vaccine made at Baltimore plant

The U.S. Food and Drug Administration said on Friday certain lots of AstraZeneca's COVID-19 vaccine manufactured at a problem-plagued Baltimore facility are fit to be shipped outside the United States.

US authorities probing Emergent BioSolutions over COVID-19 vaccine issues - filing

Drug manufacturer Emergent BioSolutions Inc said on Friday it has received inquiries and subpoenas from a swathe of U.S. authorities related to its abilities to manufacture COVID-19 bulk drug substance.

BRIEF-Emergent Says Working With AstraZeneca On Documentation For US Govt COVID-19 Vaccine Dose Shipments: Conf Call

* EMERGENT SAYS WORKING WITH ASTRAZENECA ON DOCUMENTATION FOR US GOVERNMENT COVID-19 VACCINE DOSE SHIPMENTS: CONF CALL

Emergent to resume J&J COVID-19 vaccine production at Baltimore plant

Emergent BioSolutions said it will resume production of Johnson & Johnson's COVID-19 vaccine at its troubled Baltimore facility, where operations were stopped in April after millions of doses were found to be contaminated.

REFILE-UPDATE 3-Emergent to resume J&J COVID-19 vaccine production at Baltimore plant

Emergent BioSolutions said on Wednesday it will resume production of Johnson & Johnson's COVID-19 vaccine at its troubled Baltimore facility, where operations were stopped in April after millions of doses were found to be contaminated.

Exclusive - AstraZeneca COVID-19 vaccine shipped to Canada, Mexico before adequate plant inspections

Canada and Mexico imported millions of doses of AstraZeneca's COVID-19 vaccine and offered them to the public without health officials properly inspecting the operations of the U.S. manufacturer, according to inspection records and the regulators involved.

REFILE-J&J contractor plans to resume COVID-19 vaccine production at Baltimore plant - WSJ

Johnson & Johnson contractor Emergent BioSolutions Inc plans to resume COVID-19 vaccine production at its Baltimore plant after getting approval from the U.S. Food and Drug Administration (FDA), the Wall Street Journal reported https://on.wsj.com/3iXSAfg late on Wednesday...

U.S. authorizes additional batch of J&J COVID-19 vaccine produced by Emergent

The U.S. Food and Drug Administration said on Friday it had authorized the use of an additional batch of Johnson & Johnson's one-dose COVID-19 vaccine manufactured at the problem-plagued Baltimore factory of Emergent BioSolutions Inc.

U.S. House panels expand probe into Emergent's Baltimore COVID-19 vaccine plant

Two U.S. House panels have expanded their probe into problems at Emergent BioSolutions Inc's Baltimore plant and have asked Johnson & Johnson and AstraZeneca for documents related to their selection of the contract manufacturer for their COVID-19 vaccines.

BRIEF-Congress seeks more details on Emergent's ties with Astrazeneca, J&J -New York Times

* U.S. CONGRESSIONAL INVESTIGATORS EXPAND INQUIRY INTO EMERGENT BIOSOLUTIONS AMID COVID-19 -NEW YORK TIMES

U.S. authorizes another 14 million doses of Johnson & Johnson's COVID-19 vaccine -sources

The U.S. Food and Drug Administration on Tuesday authorized around 14 million more doses of Johnson & Johnson's COVID-19 vaccine manufactured at a problem-plagued Baltimore factory, according to two sources familiar with the plans.

BRIEF-FDA Says Authorized Use For Janssen Covid-19 Vaccine Of Additional Batch Of Vaccine Drug Substance Manufactured At Emergent Facility

* FDA SAYS AUTHORIZED USE, UNDER EUA FOR JANSSEN COVID-19 VACCINE, OF ADDITIONAL BATCH OF VACCINE DRUG SUBSTANCE MANUFACTURED AT EMERGENT FACILITY

BRIEF-FDA Takes Steps To Increase Availability Of Covid-19 Vaccine

* FDA TAKES STEPS TO INCREASE AVAILABILITY OF COVID-19 VACCINE

BRIEF-EMA Aware Of Contamination In Batch Of Active Substance For COVID-19 Vaccine Janssen

* EMA SAYS COVID-19 VACCINE JANSSEN: AUTHORITIES IN EU TAKE STEPS TO SAFEGUARD VACCINE QUALITY

AstraZeneca in talks to shift COVID-19 vaccine production to Catalent factory - NYT

AstraZeneca Plc is in talks with the U.S. government to shift production of its COVID-19 vaccine from a Baltimore plant to a factory owned by Catalent Inc , the New York Times reported on Wednesday, citing people familiar with the matter.

U.S. FDA to allow Baltimore plant to resume J&J COVID-19 shot production -WSJ

The U.S. Food and Drug Administration and Johnson & Johnson are expected to announce as early as Friday that contamination problems at a COVID-19 vaccine plant in Baltimore are resolved and that vaccine production can resume, the Wall Street Journal reported on Thursday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up